

---

# COVID 19 and Clinical Trials: The Medidata Perspective

---

## Table of Contents

---

Introduction	3
Regulatory Response	4
Impact to Medidata Customers, Patients and Trials	4
Medidata Solutions to Assist Sponsors/Partners, Patients and Trials	5
Details on Medidata Solutions	6
Summary	9

# Introduction

As COVID-19 has spread, we have been monitoring its global impact on clinical trials. We see the profound impact on our industry, both at a global level but also at the site level. An analysis of the change in new patients entering clinical trials for actively recruiting studies demonstrates the significance of the impact as cities, regions, and countries have begun to restrict movement.<sup>1</sup> In China, for example, we saw an 83% decrease in new patients entering trials YoY in February 2020. We are now seeing similar trends in other affected countries. While the US didn't see a major decline in February, we've seen a decline of 62% in the first half of March. Similar declines are occurring across the EU, including France (61%) and Italy (see Exhibit 1).

## Exhibit 1



Understanding what is happening on the ground is critical to define a path forward. Sharing this data is an important step, but it's a first step. We will continue to publish updated analyses on overall industry trends throughout this pandemic and beyond.

<sup>1</sup> Based on a review of 4,069 studies currently running on the Medidata Rave EDC platform.

## Regulatory Response

As of March 21, the [European Medicines Agency \(EMA\)](#), [U.S. Food and Drug Administration \(FDA\)](#), [Medicines and Healthcare Products Regulatory Agency \(MHRA\)](#), [National Health Service \(NHS\)](#), Department of Health and Social Care (DHSC), the [Association of Clinical Research Organizations \(ACRO\)](#) and multiple IRBs (an example [here](#)) have provided emergency interim measures so that clinical trial monitoring is maintained during the COVID pandemic. In general, they agree on two critical points: that extraordinary measures must be quickly implemented, and that trials need to be adjusted as we adapt to this reality. The priority of these immediate activities must be given to the impact of the pandemic on the health and safety of the trial participant. Other key recommendations are that adjustments to clinical trial conduct should be based on a **risk assessment**, that there should be a transition to telemedicine and remote subject visits, and the use of central and remote monitoring to maintain oversight of clinical sites. An up-to-date summary by Ari Feldman, VP of Global Compliance and Strategy, of the evolving responses from clinical study regulatory agencies is available on the Medidata website [here](#).

## Impact to Medidata Customers, Patients and Trials

Real-time and detailed reporting and analytics are critical for sponsors and CROs to assess the day-to-day impact of the pandemic on a trial at the patient, site and country level and so they can quickly implement changes to mitigate the risk of trial failure.

Rapid and safe implementation of protocol amendments is vital to address both site closures and the fact that trial participants no longer receive or have access to the investigational product. Inaccessible sites mean that alternative, remote approaches to drug supply, monitoring study conduct, compliance, patient safety and data quality are needed. The more trials can be safely “virtualized,” the more likely they will be able to successfully proceed.

## Medidata Solutions to Assist Sponsors/Partners, Patients and Trials

Medidata has solutions that can be immediately leveraged by our customers to both better understand the impact of the pandemic on their trials, and to mitigate the challenges of patients unable to visit sites for their drugs and protocol-directed clinical and patient-reported data capture.

There are three main categories of challenges facing clinical trials. The following is a high level summary of these challenges and the solutions that Medidata is prepared and ready to provide:

### CHALLENGE 1: UNDERSTANDING THE EVOLVING SITUATION

**Solutions:**

- Study/sponsor level metrics and dashboards to understand impact on enrollment, patient visits, data collection, query response rates, and additional metrics to help diagnose risk areas
- Industry-wide dashboards and analysis to understand trends globally and areas of greater or lesser disruption

### CHALLENGE 2: RECONSIDERING TRIAL DESIGN TO ENABLE DATA CAPTURE

**Solutions:**

- Shift to more virtualization – reduce patient visits; minimize site burden
- Shift site mix to lower-impacted countries / regions
- Consider Synthetic Controls to reduce patient enrollment needs

### CHALLENGE 3: MAINTAINING SUPPLY AND QUALITY

**Solutions:**

- Closely monitor patient volume and drug supply to minimize supply disruptions
- Centralize data oversight and monitoring activities, bringing identification of patient anomalies earlier in the process and away from onsite identification.

## Details on Medidata’s Solutions

The following tables provide details around the Medidata’s solutions available now to assist with your trial challenges. Since some aspects of the three challenges are not mutually exclusive, some solutions may be applicable to more than one challenge.

### CHALLENGE 1: UNDERSTANDING THE EVOLVING SITUATION

#### Acorn AI Intelligent Trials

##### CHALLENGE

**Understanding the impact at site / country level across industry**

##### SOLUTION

Weekly updates at industry level (cross-sponsor) on trends in enrollment, data entry, and trial volume  
 Considering alternate countries / sites to ramp up

#### Rave RBQM

##### CHALLENGE

**Regulatory risk assessment & documentation activities**

**Travel restrictions impacting ability of site staff and monitoring resources to perform oversight responsibilities to ensure subject safety and data quality**

##### SOLUTION

To support regulatory oversight responsibilities Medidata offers 2 solutions within a Risk Based Quality Management (RBQM) framework.

The Risk Assessment Categorization Tool (RACT) supports risk assessment activities in the development and documentation of monitoring strategies by collecting critical to quality data and risk control mechanisms.

Centralized Statistical Analysis (CSA) supports the sponsors oversight responsibilities to ensure safety and data quality by next-generation analytical tools and algorithms. Medidata believes Rave CSA can bring incredible value to support the current landscape by:

- Real-time data availability for earlier data oversight
- On-demand data refreshes, enabling analyses to best comply with evolving best practices
- Real-time event incidence analysis for earlier insight into patient safety data
- Focused Key Risk Indicators (KRIs), pre-programed on areas of greatest risk
- Detection of independent and correlated data patterns and anomalies
- Detection of unknown risk trends without the need for rule programming
- Fraud detection oversight

These allow for increased efficiency in data review and centralization of review activities and risk/issue detection — a critical capability that can maintain and support sponsor oversight responsibilities and allow earlier access to data and enhance key decisions making capabilities.

## CHALLENGE 2: RECONSIDERING TRIAL DESIGN TO ENABLE DATA CAPTURE

### Rave eCOA

#### CHALLENGE

**Provide ways for missed or risked visit forms to be remotely filled out by patients on existing studies.**

#### SOLUTION

Medidata's eCOA solution can be used to convert site-based data forms to remote data forms. If study modifications are made to accommodate this approach, patients can download the patient cloud app from the app store and provide urgent data forms as needed for missed visits. **Any Rave EDC study using eCOA can have additional data forms pulled into the eCOA app and made available to patients.** Any Rave EDC studies not using eCOA can add eCOA to the project and immediately begin converting forms to remote-enabled forms.

### Rave eConsent

#### CHALLENGE

**Providing remote eConsent on trials that are already underway or are starting up.**

#### SOLUTION

Currently our iPad based consent is not set up for BYOD with a patient device. However, remote consent is possible through the use of the legacy Engage (Rave Virtual Trials/Patient Portal) platform and can be supported as a standalone activity. Some integration with Rave is possible although different usernames and passwords are used for the legacy Engage platform. The primary use case for this technology would be ongoing studies where a remote consent is required to keep the study up and running. In this case, a special instance of the Engage technology could be launched allowing patients to remotely log in and provide consent.

### Rave Patient Portal/Rave Virtual Trials

#### CHALLENGE

**Prepare for COVID-19 studies with self-quarantined patients globally. Provide insights to CDC, e.g.**

#### SOLUTION

Medidata and Dassault Systèmes are already working on an app design that can be used as a remote patient symptom tracker in France and the US. This app will function as a registry immediately (in an MVP version) and will allow hospital staff to remotely review symptoms and triage patients to the hospital only when medically necessary. In subsequent versions, we expect this to be a way to help find patients for trials and to consent them remotely before entering a site that may be performing a study or allowing patients to participate remotely.

**Provide rescue and/or new study designs that enable virtualization of visits and data capture.**

In ongoing studies and/or new study designs, the Rave Patient Portal can be used to virtualize more aspects of the study design. New generation versions of the portal will be released later this year but our existing technology is used today on ongoing virtual trials managing thousands of patients and is a fully functional and validated system for clinical research. In many cases, this version can be modified for a study that needs to accommodate remote consent, remote randomization, remote data capture, reporting and site access. Because this app is web-based, it is also easily available for all patients on all types of platforms and does not require a mobile device or device distribution.

## Acorn AI Synthetic Control Arms/Trial Design

### CHALLENGE

**Improving understanding of safety in experimental treatments (e.g., Chloroquine) that are now under review for cross-indication use.**

**Challenges closing out on-going studies given barriers completing visits**

### SOLUTION

Support research by providing aggregated data (e.g., SCD) to support understanding of expected and unexpected AEs for products being studied for COVID-19. These drugs are already marketed with a mature safety profile, but an SCD might improve the analyses above what published literature can provide. In addition, historical trial data can be compared against real-world data from claims or EMRs to provide confidence and validation in trial design, better understand inclusivity of patients populations to better reflect real world clinical practice, and potentially decrease sample size requirements for event-driven trials.

Leveraging historical clinical trial data to augment or replace control arms of trials that are in danger of high dropout or unfulfilled enrollment due to COVID-19; reduce scientific uncertainty to advance to the next phase, reduce patient enrollment burden or increase statistical power.

## CHALLENGE 3: MAINTAINING SUPPLY AND QUALITY

### Rave RTSM

#### CHALLENGE

**Patients can't get to the site for dispensation but the site is open**

**Patients can't get to the site for dispensation – sites are open but do not have supply for dispensation**

**Sites are closed and patients need a dispensation**

**Subjects are able to have an onsite visit but future visits are questionable**

**Supply chain concerns make sites want to have more buffer stock on hand or less (depending on if the concern is availability of drug or availability of shipments)**

#### SOLUTION

Site can process dispensation through Rave EDC as a visit and send the drug to the subject via a courier. Rave EDC could be updated to store the courier tracking number (collected as text data). Adding a new field would require a migration in Rave EDC.

There are several options to have drug sent to the patient from the depot or a central pharmacy. In Rave RTSM, the subject has to exist at the site where the drug supply is located. There are several options we are executing to manage transferring subjects and creating dummy shipments to allow a shipment to be sent to the patient's home from a location other than the site. We're able to work with study teams to help set up the best option based on the study design and logistic considerations.

Some of the methods above can also be used to allow a direct to patient shipment when the site is closed. Alternately, subjects may be transferred to sites that are open. We have a "How-to" procedure ready to share with you.

Multiple dispensing visits can be made in Rave EDC at the same time, providing additional IMP for the subject. If this will become standard, DND dates should be updated so that the drug does not expire over the longer time period between dispensations. Our Services team can provide specific steps that can be utilized to ensure off-cycle/unscheduled visits can be conducted without issue.

Update supply plans — [here](#) is basic learning information for supply plan settings. The supply plan can be instantly adjusted to ensure that the site is stocked with additional drug, such as calculating drug needed for additional visits. Depending on the individual study design, these methods can be combined to address any challenges faced by the study.



## Summary

Medidata is working around the clock to identify enhanced and innovative ways to assist you in analyzing the impact of the pandemic on your trials and leveraging current and developing technologies to mitigate risk through increased use of virtual capabilities, advanced analytics for operations and oversight, managing supplies and innovations like synthetic control arms to reduce the number of patients needed for evidence creation, centralization of data oversight, and identification of alternatives in supply management.

While the virus and uncertainty continue unabated, what is certain is that we continue unrelentingly to live and deliver our shared imperative to bring safe and effective therapies to market. Medidata is here for our sponsors, partners and patients throughout this remarkable and challenging time. Our mission has never been more critical than it is right now — Conquering Diseases Together.

### About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at [www.medidata.com](http://www.medidata.com) and follow us [@medidata](https://twitter.com/medidata). The Operating System for Life Sciences™.

Medidata, Medidata Rave and Acorn AI are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes. [info@medidata.com](mailto:info@medidata.com) | +1 866 515 6044